NCT05466422View on ClinicalTrials.gov

A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

September 20, 2022

Primary Completion Date

July 3, 2025

Study Completion Date

July 3, 2025

Conditions
Alzheimer Disease
Interventions
BIOLOGICAL

MK-2214

MK-2214 in escalating doses as an IV infusion on Days 1, 29, and 57

DRUG

Placebo

Placebo as an IV infusion on Days 1, 29, and 57

Trial Locations (12)

30030

CenExel iResearch, LLC ( Site 0002), Decatur

32127

Progressive Medical Research-Alzheimer's Team ( Site 0013), Port Orange

32162

Charter Research - Lady Lake ( Site 0011), The Villages

32751

K2 Medical Research ( Site 0005), Maitland

32803

Charter Research - Winter Park ( Site 0012), Orlando

33009

Velocity Clinical Research, Hallandale Beach ( Site 0001), Hallandale

33024

Research Centers of America ( Hollywood ) ( Site 0004), Hollywood

44720

Neuro-Behavioral Clinical Research ( Site 0016), North Canton

90720

Collaborative Neuroscience Research, LLC ( Site 0009), Los Alamitos

91206

California Clinical Trials Medical Group managed by PAREXEL-PAREXEL International ( Site 0007), Glendale

92868

NRC Research Institute ( Site 0015), Orange

08540

Global Medical Institutes LLC; Princeton Medical Institute ( Site 0003), Princeton

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY